Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia

Abstract

Anemia is frequent in cancer patients with chemotherapy, and has an important negative effect on health-related quality of life (QoL). Darbepoetin alfa belongs to a new class of erythropoietic proteins with a unique molecular structure and interesting properties compared with classic recombinant human erythropoietin. Darbepoetin alfa is effective for chemotherapy-induced anemia when administered once weekly at a dose of 2.25 μg/kg, as shown in two large phase III placebo-controlled trials in patients with solid tumors and hematological malignancies. Furthermore, it was safe and well tolerated. More recently attention has been focused on optimizing Darbepoetin alfa therapy. Front-loaded dosing was explored to accelerate the hemoglobin (Hb) response and effect on QoL, but this idea could not be confirmed in a large phase III study. Based on the prolonged half-life of Darbepoetin alfa, administration every 3 weeks was appealing. In a large phase III trial, noninferiority of administration of 500 μg every 3 weeks compared with the weekly dosing could be confirmed, both in terms of reduction of red blood cell transfusion, Hb parameters, and QoL. This schedule is very convenient for patients and caregivers as it allows synchronization of erythropoietic therapy and common chemotherapy schedules. Questions for future study are the optimal iron supplementation strategy and the effect of Darbepoetin alfa on outcome. This article reviews the clinical development of Darbepoetin alfa with emphasis on recent data.

Introduction

Anemia, a frequent problem in patients with cancer, has multiple possible causes. Most cancer patients have anemia related to chronic disease. Other causes are bone marrow invasion, hemolysis, nutritional deficiencies, bleeding caused by the tumor or due to treatment-induced coagulopathy. The occurrence of anemia will also be influenced by the cancer treatment: chemotherapy, especially platinum-containing chemotherapy and radiotherapy; both can induce anemia. Current cancer therapies often include dose-intense combination chemotherapy or combined chemoradiotherapy, resulting in an even more pronounced risk of myelosuppression.

Anemia has important implications for cancer patients. The most common complaint of a patient with anemia is fatigue and this symptom is known to severely reduce quality of life (QoL) (Curt 2000; Curt et al 2000). The treatment of anemia can provide real benefit for the patient improving his QoL and ensuring the best chances for achieving the planned anti-cancer therapy.

For many years transfusion was the only way of treatment for cancer-related anemia. This had several limitations: the risk of an allogeneic blood transfusion on itself, and the temporary effect and benefit for the patient. There also was a delay of anemia treatment as transfusion was usually not given in case of mild or moderate anemia, but only in case of more severe anemia (hemoglobin [Hb] ≤8 g/dL).

The primary regulator of erythropoiesis is erythropoietin (EPO), a glycoprotein hormone produced in the kidney, stimulated by tissue hypoxia. The EPO gene sequence is known since 1985 (Lin et al 1985). This allowed the development of recombinant human erythropoietin (rHuEPO), offering an alternative to transfusion in anemic patients: first in anemia due to chronic renal disease (Eschbach et al 1987, 1989) and later also in chemotherapy-induced anemia (CIA) (Cascinu et al 1994). At the moment different erythropoietic agents are available: Epoetin alfa (Procrit, Amgen, Thousand Oaks, USA/Ortho Biotech, Bridgewater, USA; Epogen, Amgen, Thousand Oaks, USA; Eprex, Janssen/Cilag, Beerse, Belgium); Epoetin beta (NeoRecormon, Roche, Basel, Switzerland) and Darbepoetin alfa (Aranesp, Amgen, Thousand Oaks, USA).

Recombinant human erythropoietin therapy has well documented clinical benefits, but frequent dosing is required and response rate is variable. Darbepoetin alfa is a new-generation molecule with clear advantages compared with rHuEPO. This article provides an overview of the evidence for the use of Darbepoetin alfa in patients with CIA.

Darbepoetin alfa

Erythropoietin research demonstrated that the carbohydrate content, more specifically the sialic acid residues, is the determining factor for the in vivo (not in vitro) biological activity. Studies on isolated rHuEPO isoforms showed that molecules with the highest sialic acid content had the longest plasma half-life and the greatest in vivo bioactivity, but a lower receptor affinity (Darling et al 2002). Clearance and not receptor affinity seemed to be the key factor for enhanced in vivo bioactivity. Five amino-acid changes were designed in Darbepoetin alfa compared with rHuEPO. This enabled the addition of 2 new carbohydrate chains at unique sites of the protein backbone, resulting in a total of 5 N-linked carbohydrate chains compared with 3 in rHuEPO. In summary, the new molecule was distinct from epoetin with regard to physical size, molecular weight, carbohydrate, and sialic acid content. Darbepoetin alfa works through interaction with the EPO-receptor to promote proliferation, survival, and differentiation of hematopoietic cells in a manner consistent with the activity of endogenous EPO (Egrie et al 2003).

In a comparative study of rHuEPO and Darbepoetin alfa in vivo, Egrie et al (2003) demonstrated that Darbepoetin alfa has a 3-fold longer circulating half-life in rats and dogs, and that it is more potent than rHuEPO.

Pharmacokinetics and pharmacodynamics

Pharmacokinetic studies with Darbepoetin alfa have been completed in a range of patient populations, including healthy volunteers, patients with end-stage renal failure, and with CIA. In those studies in which comparisons to rHuEPO have been done, Darbepoetin alfa was consistently cleared more slowly, with a longer terminal half-life compared with rHuEPO (Allon et al 2002). Pharmacokinetic properties of Darbepoetin alfa administrated subcutaneously were studied in patients receiving chemotherapy every 3 weeks. Peak concentration (median) occurred at 62 and 72 hours post-dose, and mean (SD) terminal half-life ranged from 87.7 (26.0) to 60.9 (22.3) hours (Heatherington et al 2001). These studies already suggested that dosing less frequently than the 3-times-weekly doses used for rHuEPO might be effective.

Pharmacokinetics of Darbepoetin alfa also have been studied in function of weight, based on a typical oncology population and with reserve to the weight extremes. Weight did not seem to have an influence on the efficacy of the molecule in a phase II randomized, double-blind study comparing a weight-based versus a fixed dose (Hesketh et al 2004).

Safety

Darbepoetin alfa is a safe and well-tolerated drug. In all of the clinical studies reported, adverse events were generally associated with malignant disease and the toxic effects of chemotherapy, with no difference between placebo and Darbepoetin alfa arms. The most frequently reported adverse events were gastrointestinal (nausea and vomiting) and constitutional symptoms (fatigue). A broad range of doses and different administration schedules have been studied, with no demonstrated dose-effect relationship for adverse events. Possible thromboembolic complications when using erythropoietic agents are of particular concern. A recently published meta-analysis did not suggest an increased risk (Bohlius, Langensiepen, et al 2005), but an update of that work, now including 57 trials with 9353 patients, reported an increased risk of thromboembolic adverse effects (relative risk [RR] 1.67, 95% confidence index [CI] 1.35–2.06) (Bohlius, Wilson, et al 2005). Hedenus studied which criterion of rise in Hb during Darbepoetin alfa therapy was the best discriminator between natural Hb variability and increased risk of thrombotic events (Hedenus, Canon, et al 2005). Three definitions of rapid rise in Hb were considered (=2 g/dL increase in 28 days; =1.5 g/dL increase in 21 days; and =1 g/dL increase in 14 days). The 2 g/dL per 28 days was the best discriminator, while the 1 g/dL rule resulted in an excessive rate of “false-positive” risk, even in the absence of erythropoietic therapy. The elucidation of this safety aspect is crucial for the future of eryhropoietic therapy.

One study evaluated fixed dose versus weight-based dose of Darbepoetin alfa and observed no safety problems, with a reservation for the extremes of weight, because of the limited number of these type of patients in the study (Hesketh et al 2004).

Pure red cell aplasia (PRCA) in association with neutralizing antibodies to endogenous EPO has been observed in patients with chronic kidney disease who had been treated by subcutaneous injection of one brand of Epoetin alfa (Eprex) (Casadevall et al 2002; Macdougall 2004). To date, there is no evidence of neutralizing antibodies to Darbepoetin alfa.

An other ongoing safety issue is the exclusion of any adverse effect concerning progression-free or overall survival in patients treated with erythropoietic agents (see “Effect on disease outcome”).

Clinical efficacy

Treatment of CIA with Darbepoetin alfa administered once weekly

The clinical efficacy of Darbepoetin alfa once weekly has been established in several phase II and III randomized trials (Table 1).

Table 1.

Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa administered once weekly

Ref	n	Study design	Study population	Main results
(Glaspy et al 2002)	269	Phase II randomized, open label	Solid tumors; receiving chemotherapy; Hb ≤ 1.0 g/dL	Evident dose-response relationship for Hb response up to doses of 4.5 μg/kg
		Darbepoetin alfa: 0.5, 1.0, 1.5, 2.25, 4.5, 6.0, and 8.0 μg/kg/week versus Epoetin alfa: 150I U/kg 3 times/week (increase to 300 IU/kg) 12-week treatment
(Hedenus et al 2002)	66	Phase II randomized, double-blind	Lymphoproliferative malignancies receiving chemotherapy; Hb ≤ 11.0 g/dL	Proportion of patients achieving Hb response is higher with any dose of Darbepoetin alfa compared with placebo
		Darbepoetin alfa: 1.0, 2.25, and 4.5 μg/kg/week versus Placebo: 12-week treatment
(Vansteenkiste et al 2002)	314	Phase III randomized, double-blind	Lung cancer receiving platinum-based chemotherapy; Hb ≤ 11 g/dL	Significant reduction of incidence of transfusion and number of units transfused.
		Darbepoetin alfa: 2.25 μg/kg/week versus Placebo: 12-week treatment
(Hedenus et al 2003)	344	Phase III randomized, double-blind	Lymphoproliferative malignancies receiving chemotherapy; Hb ≤ 11 g/dL	Better hematopoietic response and QoL. Significant reduction of RBC transfusions and higher Hb response.
		Darbepoetin alfa: 2.25 μg/kg/week versus Placebo: 12-week treatment

Abbreviations: Hb, hemoglobin; RBC, red blood cells; QoL,quality of life.

Glaspy et al (2002) administered Darbepoetin alfa to anemic patients with solid tumors receiving chemotherapy at doses of 0.5 μg/kg to 8.0 μg/kg once a week (n=216); Epoetin alfa, in an initial dose of 150 U/kg 3 times weekly, with possible dose increase to 300 U/kg, 3 times weekly was the control arm (n=53). There was an evident dose-response relationship for Hb response (ie, an increase in Hb concentration from baseline of at least 2 g/dL) up to doses of 4.5 μg/kg. At this dose, 76% of the patients had a Hb response (95% CI 59–94). In a later part of this study, administration of Darbepoetin alfa every 2 weeks proved to result in similar efficacy. In another phase II randomized study, Hedenus et al (2002) evaluated the efficacy of 3 doses of Darbepoetin alfa (1.0 μg/kg, 2.25 μg/kg, and 4.5 μg/kg) (n=55) versus placebo (n=11) in anemic patients with lymphoproliferative malignancies receiving chemotherapy. The proportion of patients achieving Hb response was higher with any dose of Darbepoetin alfa compared with placebo (45%, 55%, 62% and 10% for a dose of 1.0 μg/kg, 2.25 μg/kg, and 4.5 μg/kg and placebo respectively; p<0.01).

Subsequently, two large, placebo-controlled phase III trials were conducted that confirmed the efficacy of Darbepoetin alfa at a dose of 2.25 μg/kg per week. Vansteenkiste et al (2002) randomly assigned 314 anemic lung cancer patients receiving platinum-containing chemotherapy (Hb <11 g/dL), to either Darbepoetin alfa (2.25 μg/kg per week) or placebo. Primary endpoint was the proportion of patients who needed red blood cell (RBC) transfusion. There was a statistically significant reduction of both the incidence of transfusion (reduction of 25% compared with placebo, 95% CI 14–36, p<0.001) and the number of units transfused (difference of 1.25 units, 95% CI 0.65–1.84, p<0.001). The proportion of patients achieving a hematopoietic response and those with a decrease in fatigue also were significantly in favour of Darbepoetin alfa. Hedenus et al (2003) conducted a similar study in 344 anemic patients with lymphoproliferative malignancies receiving chemotherapy. A significant higher Hb response (60% [95% CI 52–68] achieving a Hb response in the Darbepoetin alfa cohort) and a statistically significant reduction of transfusions (31% vs 48%, p<0.001) were noted.

The effect of Darbepoetin alfa was also studied in patients with anemia of cancer not treated with chemotherapy (Smith et al 2003). The first open-label part of this trial included 102 patients, who received doses of 0.5 μg/kg to 4.5 μg/kg once weekly for 12 weeks. Hematopoietic response was reached in 70% (95% CI 53– 88) at the 2.25 μg/kg dose, and in 100% at the 4.5 μg/kg dose, both largely superior compared with placebo (10%, 95% CI 0–24).

Treatment of CIA with Darbepoetin alfa administered every 3 weeks

Many chemotherapy schedules for solid tumors are administered in a cycle length of 3 weeks. Therefore, extension of the dosing interval of erythropoietic therapy to once every 3 weeks was considered to be of major interest. Darbepoetin alfa, with its longer serum half-life compared with rHuEPO, was an ideal candidate to explore this option (Table 2).

Table 2.

Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa administered once every 3 weeks

Ref	n	Study design	Study population	Main results
(Kotasek et al 2003)	249	Phase II randomized, double-blind	Solid tumors receiving chemotherapy; Hb ≤ 11.0 g/dL	Evident dose-response relationship for hematopoietic response and mean change in Hb up to doses 12.0 μg/kg
		Darbepoetin alfa: 4.5, 6.75, 9.0, 12.0, 1 3.5, and 15 μg/kg every 3 weeks versus Placebo: 12-week treatment		Lower percentage of patients receiving RBC transfusions (any group) compared with placebo
(Glaspy et al 2005)	81	Phase II randomized, open label	Non myeloid malignancies receiving chemotherapy; Hb ≤ 11 g/dL	Similar mean increase in Hb after 6 weeks
		Darbepoetin alfa 6.75 μg/kg every 3 weeks synchronous (day 1)versus asynchronous (day 15) with chemotherapy: 16-week treatment
(Canon et al 2006)	705	Phase III randomized, double blind	Non-myeloid malignancies receiving chemotherapy; Hb ≤ 11 g/dL	Noninferiority of every 3 weeks dosing versus every week dosing
		Darbepoetin alfa 500 μg every 3 weeks versus Darbepoetin alfa 2.25 μg/kg every week: 16-week treatment

Abbreviations: Hb, hemoglobin; RBC, red blood cells

Kotasek et al (2003) conducted a placebo-controlled, safety and dose-finding study with administration of Darbepoetin alfa every 3 weeks in anemic patients with solid tumors (n=249). Doses ranged from 4.5 μg/kg to as high as 15 μg/kg in the active arms. Administration of a high dose every 3 weeks proved to be safe. There was a dose-response relationship for Hb and hematopoietic response up to doses of 12.0 μg/kg, and the optimal dose for further development was set at 6.75 μg/kg every 3 weeks.

Synchronous administration of chemotherapy and erythropoietic therapy on an every 3 weeks basis was the most attractive option for both patients and caregivers. Because of the negative historical experience with synchronous use of neutrophil growth factors and chemo(radio)therapy (Bunn et al 1995), similar concerns were raised about administration of erythropoietic agents on the day when bone marrow precursors were hit by chemotherapy. This important question was addressed in a phase II randomized study (Glaspy et al 2005). As many aspects of pharmacokinetics of endogenous and recombinant human erythropoietin in that setting were not clear, both efficacy and pharmacokinetic parameters were recorded. Patients (n=81) received chemotherapy every three weeks and were randomized 1:1 to receive Darbepoetin alfa 6.75 μg/kg once every three weeks asynchronously (day 15) or synchronously (day 1) with chemotherapy. The primary endpoint (mean increase in Hb after 6 weeks) was similar in both groups: 1.0 g/dL (95 %: CI 0.6–1.3) asynchronous, 1.0 g/dL (95 % CI: 0.6–1.5) synchronous (p=0.45) (Figure 1). No significant differences were noted concerning the importance or rate of Hb change, pointing at similar efficacy of synchronous or asynchronous dosing. The pharmacokinetic data showed an increase of endogenous EPO concentrations in both groups starting 6 hours after chemotherapy and lasting one week. A possible explanation for this phenomenon is a decreased clearance by the bone marrow caused by the myelosuppressive effect of chemotherapy. Synchronous dosing of chemotherapy and Darbepoetin alfa also resulted in an increase in maximal concentration and area under the curve–time curve of Darbepoetin alfa compared with asynchronous dosing. The argument that bone marrow contributes to clearance of erythropoietic proteins is also plausible here. The net result is a higher availability of Darbepoetin alfa on the days when myelosuppression due to chemotherapy is more prominent, resulting in similar efficacy as for asynchronous administration.

Figure 1.

Mean hemoglobin over time by chemotherapy cycle in the phase II randomized study with asynchronous (filled circles) or synchronous administration (empty circles) of Darbepoetin alfa administered every 3 weeks. Error bars represent 95% confidence limits. Copyright © 2005. Reproduced with permission from Glaspy J, Henry D, Patel R, et al. 2005. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer, 41:1140–9.

The regimen of Darbepoetin alfa every 3 weeks was confirmed in a large phase III study (n=705), that was reported recently (Canon et al 2006). It was a randomized double-blind, double-dummy, active-controlled study conducted in anemic (Hb <11 g/dl) patients with chemotherapy for non-myeloid malignancy, comparing weekly administration of 2.25 μg/kg Darbepoetin alfa versus a fixed dose of 500 μg every three weeks. The primary endpoint was the incidence of RBC transfusions from week 5 to the end of treatment. The study had a noninferiority design: the upper limit of the 95% CI of the difference in the incidence of RBC transfusions had to be below 12.5%. This number was based on the average difference in transfusion rates of 23% in the two phase III studies with weekly dosing (Vansteenkiste et al 2002; Hedenus et al 2003). Adjusted for stratification factors, the incidence of transfusions was 19% (95% CI 15–24) for the every three weeks and 28% (95% CI 23–33) for the every-week group, a difference well below the limit of noninferiority. The validity of Darbepoetin alfa administered every three weeks is further illustrated in Figure 2. The RBC transfusion rates are consistently low in all actively treated groups of four phase III trials with this agent, two placebo-controlled ones (Vansteenkiste et al 2002; Hedenus et al 2003), one with front-loaded dosing (Kotasek et al 2004), and the every 3 weeks study (Canon et al 2006).

Figure 2.

Red blood cell transfusion rates in four phase III trials with Darbepoetin alfa. Data from two placebo-controlled studies (Vansteenkiste et al 2002; Hedenus et al 2003), the front-loading study (Kotasek et al 2004), and the every 3 weeks dosing study (Canon et al 2006).

Clinical trials on treatment of CIA with Darbepoetin alfa focusing on special issues

Front-loaded dosing

Another attractive hypothesis to improve the efficacy of erythropoietic therapy has been the front-loading approach with the purpose of achieving an optimal and fast response. This would also permit to identify non-responders early. Therapy was started with a dose-intense schedule during a correction phase (the time needed to reach a Hb value of ≥12 g/dL) with the intent to decrease the dose or increase the dose interval during a maintenance phase (Table 3).

Table 3.

Clinical trials on treatment of chemotherapy-induced anemia with Darbepoetin alfa focusing on special issues

Ref	n	Study design	Study population	Main results
Front-loaded dosing
(Glaspy et al 2003)	127	Phase II randomized, double-blind	Solid tumors receiving chemotherapy; Hb ≤ 11 g/dL	Safe and effective improvement of Hb concentration
		Darbepoetin alfa : 4.5 μg/kg/week until Hgb=12 g/dL, then 1.5 μg/kg/week (Group 1) 4.5 μg/kg/week for 4 weeks, then 2.25 μg/kg/week (Group 2) 4.5 μg/kg/week for 4 weeks, then 3.0 μg/kg every 2 weeks (Group 3) versus rHuEPO 40 000 U/week (increase to 60 000 U/week): 12-week treatment
(Hesketh et al 2004)	243	Phase II randomized, double-blind	Non-myeloid malignancies, receiving chemotherapy; Hb ≤ 11.0 g/dL	High hematopoietic response in both the fixed-dose group (86%) and weight-based dose group (84%). Similar median time to hematopoietic response. Hb concentrations maintained at target levels for up to 16 weeks in both groups
		Darbepoetin alfa fixed dose (325 μg/week) versus Darbepoetin alfa weight-based dose (4.5 μg/kg/week), until Hb = 12.0 g/dL, followed by administration every 3 weeks: 16-week treatment
(Kotasek et al 2004)	727	Phase III randomized, double-blind, active-controlled	Non-myeloid malignancies, receiving chemotherapy; Hb ≤ 11.0 g/dL	Noninferiority of front-loading compared with standard weekly dosing Better hematopoietic response in standard weekly dosing
		Darbepoetin alfa 2.25 μg/kg/week versus Darbepoetin alfa 4.5 μg/kg/week for 4 weeks, then 4.5 μg/kg every 3 weeks
Subcutaneous versus intravenous administration
(Justice et al 2005)	118	Phase II randomized, open label	Non-myeloid malignancies, receiving chemotherapy; Hb ≤ 11.0 g/dL	Equal efficacy of Darbepoetin alfa administered IV or SC
		Darbepoetin alfa 4.5 μg/kg for 6 weeks, followed by 4.5 μg/kg every 3 weeks for 12 weeks subcutaneous versus Same schedule intravenous 18-week treatment

Abbreviations: Hb, hemoglobin; IV, intravenous; SC, subcutaneous.

Two phase II trials explored this concept. In a randomized, active-controlled pilot trial (n=127) by Glaspy et al (2003), patients were randomly assigned to 1 of 4 treatment groups for a duration of 12 weeks. In the active control arm, patients received 40 000 U rHuEPO per week, with escalation to 60 000 U per week for non-responders. The Darbepoetin alfa arms were at doses of 4.5 μg/kg per week until Hb concentration was ≥12 g/dL, then 1.5 μg/kg per week (group 1), 4.5 μg/kg per week for 4 weeks, followed by 2.25 μg/kg per week for 8 weeks (group 2) or 3.0 μg/kg every 2 weeks (group 3). A marked increase of the Hb level was observed early in the treatment period (week 5) for all the front-loaded regimens. Median time to Hb response was 50 days for 2 of the 3 groups treated with Darbepoetin alfa. The proportion of patients achieving Hb response varied from 58% to 65% over the 3 Darbepoetin alfa groups. The limited number of patients permitted not to make final conclusions concerning efficacy endpoints but the data were encouraging. Another open label, phase II randomized study by Hesketh et al (2004) was promising as well. In a front-loaded schedule, 243 patients received Darbepoetin alfa every week during the correction phase (ie, the phase until a Hb concentration ≥12 g/dL was achieved without a RBC transfusion in the previous 4 weeks) followed by an administration every 3 weeks during the maintenance phase (ie, until week 16). Patients were divided into a group receiving a fixed-dose (325 μg) and a group receiving a weight-based dose (4.5 μg/kg) of Darbepoetin alfa. Almost 80% of the patients achieved Hb correction in both groups. Median time to correction was 42 days, identical for both groups.

These promising findings were further explored in a large double-blind, double-dummy, randomized phase III study in 727 patients with non-myeloid malignancies and CIA (Hb ≤11 g/dL) (Kotasek et al 2004). The expected advantage of front-loaded dosing could not be confirmed. Patients were treated with either Darbepoetin alfa 4.5 μg/kg per week for 4 weeks, followed by maintenance with 4.5 μg/kg every 3 weeks, or Darbepoetin alfa 2.25 μg/kg per week, for an interval of 16 weeks. The primary aim of the study was to prove noninferiority to standard weekly dosing by evaluating the number of transfusions. No difference in number of transfusions from week 5 to the end of treatment was seen between both groups: 24% (95% CI 19–28) for the 2.25 μg/kg every-week group versus 25 % (95% CI 20–30) for the front-loaded group. The hematopoietic response level was higher when Darbepoetin alfa was administered every week (87%, 95% CI 83–91) compared with the correction/maintenance approach (68%, 62–73). In conclusion, front-loading using this administration schedule of Darbepoetin alfa was of no additional benefit compared with standard therapy, taken in account that standard therapy appeared to be very efficient.

Subcutaneous versus intravenous administration

To make Darbepoetin alfa therapy still more convenient, especially for patients with central venous access, the efficacy of intravenous administration has been studied (Table 3). A total of 120 anemic patients with non-myeloid malignancies planned to receive 12 additional weeks of chemotherapy, were randomly assigned (1:1 allocation) to subcutaneous or intravenous administration (Justice et al 2005). During a correction phase lasting from week 1 to 6, each group received Darbepoetin alfa 4.5 μg/kg weekly, followed by a less frequent dose of 4.5 μg/kg every 3 weeks during a maintenance phase (until week 15). Primary endpoint was the change in Hb from baseline. The mean change in Hb (intention-to-treat) was 1.0 g/dL (95 % CI 0.6– 1.4) in the intravenous group and 1.4 g/dL (95% CI 1.0– 1.9) in the subcutaneous group. This difference between both groups was not statistically significant. Results for other endpoints such as hematopoietic response and number of RBC transfusions were similar as well. Pharmacokinetic analyses showed no accumulation of Darbepoetin alfa, even not during the correction phase. Efficacy is similar considering both ways of administration.

Future issues with Darbepoetin alfa therapy

Iron supplementation

Another open question in the treatment of CIA is the role of iron supplementation. When plasma iron values and iron reserve values are low (saturation <20%), iron substitution seems attractive. Whether oral or intravenous iron has to be preferred remains unsolved. Intravenous iron improves Hb response and decreases dosage requirements in patients with anemia of kidney disease, but its effect is less documented in cancer patients.

In a prospective, multicenter, open-label, randomized trial, Auerbach et al (2004) studied 157 patients with chemotherapy-related anemia (Hb <10.5 g/dL) receiving rHuEPO 40 000 U once weekly with either no iron, oral iron 325 mg twice daily, or iron dextran intravenously. Mean Hb increase was significantly better with intravenous iron than with no or oral iron. The hematopoietic response was 68% with intravenous iron, compared with 36% with oral iron, and 25% without iron. The interpretation of these findings is difficult, as the very low hematopoietic response in the cohorts with oral or no iron is not in line with any other study with erythropoietic agents. This suggests inclusion of a special selection of patients, probably those with severe iron deficiency, as one of the inclusion criteria of the trial was an iron saturation below 19%.

A study in a less selected group of patients receiving chemotherapy is ongoing. The hematopoietic response after 16 weeks of treatment with 500 μg of Darbepoetin alfa every three weeks with either intravenous iron versus oral or no iron supplementation according to local practice will be compared. This study will hopefully lead to a better understanding of the iron issue.

Effect on disease outcome

The positive effect of the treatment of anemia on health-related QoL is well established. It is also clear that anemia is an independent negative prognostic factor, with growing evidence for other consequences of anemia in patients with cancer such as increased resistance to therapy, increased tumor invasiveness, and metastatic potential, resulting in reduced survival (Caro et al 2001).

The question of whether correction of anemia during oncological treatment can favourably influence outcome, however, remains unresolved at the moment. Encouraging findings in this respect were present in recent randomized trials. In our phase III study, the hypothesis of a potentially better survival in patients with small cell lung cancer treated with Darbepoetin alfa versus those receiving placebo was generated (Vansteenkiste et al 2002). A possible relationship between increased Hb and better survival was also reported in a phase III study on 375 anemic (Hb <10.5 g/dL) patients with solid or nonmyeloid hematological malignancies treated with non-platinum chemotherapy (Littlewood et al 2001). A similar, but also nonsignificant, trend towards improved survival with rHuEPO was observed in another placebo-controlled study (Witzig et al 2004).

On the other hand, caution was raised recently, following two studies with rHuEPO in breast cancer and head and neck cancer reporting negative survival results. The first one was a placebo-controlled study in patients with metastatic breast cancer that was prematurely stopped because of a statistically significant higher mortality in the Epoetin alfa group (Leyland-Jones et al 2005). There was an excess mortality during the first 4 months of treatment, due to an increased incidence of both tumor progression as well as thrombotic vascular events. After the initial excess in deaths in the active arm, overall time to progression was similar in both arms. No definitive conclusions can be made regarding tumor progression rates, however, because of the lack of data on many potentially important prognostic factors that might have affected study outcome. External review by an independent group of researchers even suggested worse prognostic features for the Epoetin alfa group in terms of age, performance status, disease extent, degree of baseline anemia, and thromboembolic risk.

The second study was a randomized double-blind placebo-controlled study including 351 anemic patients with head and neck cancer (Henke et al 2003). Locoregional progression-free survival (the primary endpoint) was worse with Epoetin beta than with placebo (adjusted RR 1.62, 95% CI 1.22–2.14, p=0.0008). The study has been criticized for several reasons. First, there were potential imbalances in study populations across arms, as there were more smokers (with possibly increased co-morbidity) and relapsed patients in the Epoetin beta arm, and as no data on performance status were available. Second, protocol violations were present in 36% of the patients, and the difference in outcome was no longer significant when the analysis was restricted to the as-per-protocol treated patients. Third, the Hb ranges were far above those usually reported in other studies on erythropoietic agents: treatment changes were to be made only if Hb values exceeded 14 g/dL in women or 15 g/dL in men, or when Hb increased more than 2 g/dL in one week. The mean Hb concentration at 4 weeks in this cancer population was 14.8 g/dL.

The results of these two studies (Henke et al 2003; Leyland-Jones et al 2005) are in contrast with previous trials (Littlewood et al 2001; Vansteenkiste et al 2002; Witzig et al 2004), and with the conclusion of a published meta-analysis based on 27 trials involving 3287 adult patients. Overall, there was a slightly more favourable meta-analytic survival outcome in the erythropoietin-treated patients (hazard ratio [HR] 0.81, 95% CI 0.67–0.99). This meta-analysis has been updated recently. The study now concerns 57 trials with 9353 patients, including the two trials with negative impact on survival. Positive results on reduced risk of transfusion and presence of hematological response were maintained. The incidence of thromboembolic complications was increased (as mentioned in “Safety”). As for survival, the initially suggested possible benefits did no longer hold true (HR 1.08; 95% CI 0.99–1.18; 42 trials, n=8167). The authors tried to explain the change in conclusion by pointing at possible factors such as thromboembolic complications, tumor progression issues, but also the methodological limitations of some studies. As a whole, the evidence confirms the value of erythropoietic therapy in reducing transfusions and improving QoL in established indications such as CIA, but further elucidation of the effect of erythropoietic therapy when used to obtain high-normal Hb values in an attempt to improve outcome is clearly needed.

It should also be noted that no similar problems with Darbepoetin alfa have occurred. In a recent combined analysis of four studies, including the two randomized, double-blind, placebo-controlled phase III studies of weekly dosing of Darbepoetin alfa, the prospectively defined short-and long-term progression-free and overall survival endpoints were not different across arms (HR 0.92; 95% CI 0.78–1.07; 0.95; 95% CI 0.78–1.16, respectively) (Figure 3) (Hedenus, Vansteenkiste, et al 2005). Different erythropoietic proteins such as Epoetin alfa or beta or Darbepoetin alfa have unique pharmacokinetics, and this may be accompanied by distinct effects on survival. The dose and schedule of erythropoietic therapy may also be important, as well as the chosen target Hb to act on survival. Several ongoing placebo-controlled trials with Darbepoetin alfa in different tumor types are studying these important questions.

Figure 3.

Combined analysis of survival from four Darbepoetin alfa studies in chemotherapy-induced anemia.

Conclusion

Anemia is frequent in cancer patients with chemotherapy, and has an important negative effect on health-related QoL. Darbepoetin alfa, the first of a novel generation of erythropoietic agents, has been confirmed to be effective when administered once weekly at a dose of 2.25 μg/kg in two large phase III placebo-controlled trials in patients with solid tumors and hematological malignancies. Furthermore, it was a safe and well tolerated drug. More recently, different other issues have been studied. Front-loaded dosing was explored to accelerate the Hb response and effect on QoL. Phase II data were promising, but no benefit compared with standard dosing could be shown in a large phase III study.

In an attempt to further increase convenience for patients and caregivers, extending the dose interval to every three weeks and thereby adapting the dose frequency to the most common chemotherapy schedules was studied. In a large phase III trial, administration of 500 μg every 3 weeks was not inferior to the weekly dosing, both in reduction of RBC transfusion, Hb parameters, and QoL. This clinically attractive schedule has been approved by the European Agency for the Evaluation of Medicinal Products (EMEA) and approval by the Food and Drug Administration (FDA) is pending. When using Darbepoetin alfa every 3 weeks, efficacy is similar when Darbepoetin alfa is administered synchronous or asynchronous with chemotherapy. For daily practice it is obvious that administration on the same day just prior to the chemotherapy is preferred.

Issues for future study are the optimal iron supplementation strategy and the effect of erythropoietic therapy on outcome. The last issue is a hot topic, especially after recent negative results of two outcome studies with rHuEPO that targeted normal to high Hb levels. No final conclusions can be made, as these two studies had methodological flaws and are in conflict with other studies. The influence of erythropoietic therapy on outcome remains a very attractive field of investigation, and the results of ongoing survival studies are eagerly awaited.

Acknowledgments

Johan Vansteenkiste is holder of the Amgen Fund in Supportive Care at the Catholic University of Leuven, Belgium.